Barbesaclone (Epilepsy = All indications) updated on 04-22-2025

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16575
R69632		 Battino (Barbexaclone) (Epilepsy), 2024 Major congenital malformations (MCMs) early pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 0.70 [0.04;11.59] C 0/23   110/3,584 110 23
ref
S6508
R17923		 Canger (Barbesaclone), 1999 All type of malformation 1st trimester prospective cohort unexposed, sick Adjustment: No no data 1/1   0/25 1 1
ref
Total 2 studies NaN [NaN;NaN] 111 24
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Battino (Barbexaclone) (Epilepsy), 2024Battino, 2024 1 0.70[0.04; 11.59]11023NaN%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Canger (Barbesaclone), 1999Canger, 1999 2 Out of scale-51.00[NaN; NaN]11NaN%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = NaN% Out of scaleNaN[NaN; NaN]111240.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Barbexaclone) (Epilepsy; 2: Barbesaclone;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies Battino (Barbexaclone) (Epilepsy), 2024 Canger (Barbesaclone), 1999 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick Canger (Barbesaclone), 1999 1 exposed to other treatment, sickexposed to other treatment, sick 0.70[0.04; 11.59]11023 -NABattino (Barbexaclone) (Epilepsy), 2024 1 Tags Adjustment   - No  - No Battino (Barbexaclone) (Epilepsy), 2024 Canger (Barbesaclone), 1999 2 All studiesAll studies Battino (Barbexaclone) (Epilepsy), 2024 Canger (Barbesaclone), 1999 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Canger (Barbesaclone), 1999 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.70[0.04; 11.59]11023 -NABattino (Barbexaclone) (Epilepsy), 2024 10.510.01.0